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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Riociguat for Pulmonary Hypertension
To the Editor: With regard to the articles on 
the Chronic Thromboembolic Pulmonary Hyper-
tension Soluble Guanylate Cyclase–Stimulator 
Trial 1 (CHEST-1) and the Pulmonary Arterial 
Hypertension Soluble Guanylate Cyclase–Stimu-
lator Trial 1 (PATENT-1) by Ghofrani et al. (July 25 
issue)1,2 and the corresponding editorial by Archer,3 
we agree that pharmacotherapy should be avail-
able to patients with inoperable disease. However, 
the observed improvements in exercise capacity 
with riociguat for chronic thromboembolic pul-
monary hypertension are inferior in magnitude, 
and their durability is unknown, as compared 
with reported outcomes after surgery, which is 
associated with an approximate 2% mortality 
and is curative in many patients.4 The importance 
of establishing operability in patients with chron-
ic thromboembolic pulmonary hypertension is 
paramount before the initiation of medical ther-
apy, and the definition of operability should be 
determined at experienced surgical centers. Our 
center has performed roughly 3000 operations, 
and many of our patients have had distal or seg-
mental obstruction, high levels of pulmonary 
vascular resistance, or both and so have been 
deemed to have inoperable disease at some centers, 
but these patients have had excellent outcomes 
with interventions performed by experienced sur-
geons. Furthermore, medical therapy in chronic 
thromboembolic pulmonary hypertension may 
delay the operation unnecessarily and make re-
moval of the organized thrombus more difficult.5 
Accordingly, we emphasize caution with the use 
of temporizing therapies for a disease for which 
more definitive approaches are viable.
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To the Editor: The oral soluble guanylate cyclase 
stimulator riociguat may increase the sensitivity 
of soluble guanylate cyclase to endogenous nitric 
oxide, resulting in increased production of its in-
tracellular second messenger, cyclic guanosine 
monophosphate (cGMP). Evidence suggests that 
enhanced activation of the cGMP pathway may 
lead to cGMP-dependent protein kinase 1–medi-
ated phosphorylation of phosphodiesterase-5 and 
to an increase in phosphodiesterase-5 activity.1 
Activation of phosphodiesterase-5, in turn, may 
enhance cGMP hydrolysis, limiting the amplitude 
and duration of a cGMP signal and consequently 
the effect of riociguat.1 This observation suggests 
that the use of a combination of riociguat plus a 
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phosphodiesterase-5 inhibitor such as sildenafil, 
as compared with the use of either agent alone, 
may improve outcomes.
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To the Editor: The CHEST-1 investigators showed 
that riociguat significantly improved exercise ca-
pacity and pulmonary vascular resistance in pa-
tients with chronic thromboembolic pulmonary 
hypertension. According to the 2011 guidelines 
for the treatment of chronic thromboembolic 
pulmonary hypertension, patients with this con-
dition should receive lifelong anticoagulation, 
usually with doses of vitamin K antagonists ad-
justed to a target international normalized ratio 
between 2.0 and 3.0.1 However, there is no men-
tion of the current anticoagulation status of the 
patients with chronic thromboembolic pulmo-
nary hypertension in CHEST-1. Anticoagulation 
therapy could be an important confounding fac-
tor for the efficacy analysis, especially in patients 
with inoperable chronic thromboembolic pulmo-
nary hypertension. In the simultaneously pub-
lished article on PATENT-1, a subgroup analysis 
showed that the functional benefits of riociguat 
therapy tended to be greater in patients who had 
received prostanoids; this finding was also men-
tioned in the accompanying editorial. Although 
patients in CHEST-1 were excluded if they had 
received concomitant medical therapy, previous 
medical therapy should be considered as a factor 
in that analysis.
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To the Editor: In their article on riociguat for 
the treatment of pulmonary arterial hyperten-
sion, Ghofrani et al. report the inclusion of 221 
of 443 symptomatic patients with pulmonary ar-
terial hypertension (50%) who were not receiving 
background therapy. According to the guidelines 
of the European Society of Cardiology and the 
European Respiratory Society for the treatment 
of pulmonary hypertension, published in 2009, 
all patients who are in World Health Organiza-
tion (WHO) functional class II to IV should re-
ceive targeted therapy for pulmonary arterial hy-
pertension (the recommendation is class I, level 
of evidence A).1 A total of 22% of patients were in 
WHO functional class III or IV without appropri-
ate treatment for pulmonary arterial hyperten-
sion before inclusion in the current study; these 
patients had a significant decrease in the 6-min-
ute walk distance (−37 m) after receiving placebo 
for 12 weeks. A meta-analysis of clinical trials 
involving patients with pulmonary arterial hyper-
tension, including 3140 symptomatic patients, 
showed a 43% reduction in mortality in the active-
treatment groups as compared with the placebo 
groups during an average of 14 weeks.2 Data are 
lacking regarding head-to-head risks and bene-
fits of established effective agents so that clini-
cians and patients may make informed clinical 
decisions.3 Furthermore, it seems to be unethical 
to perform placebo-controlled trials involving 
symptomatic patients with pulmonary arterial 
hypertension who have not received targeted 
therapy for pulmonary arterial hypertension and 
who are at increased risk for death with placebo.
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The Authors Reply: Auger and Jamieson high-
light the importance of pulmonary endarterec-
tomy as a potentially curative treatment for chron-
ic thromboembolic pulmonary hypertension. In 
CHEST-1, rigorous measures were taken to ensure 
that only patients with chronic thromboembolic 
pulmonary hypertension that was adjudicated to 
be technically inoperable or who had persistent 
or recurrent pulmonary hypertension after pul-
monary endarterectomy were included. An ex-
pert committee to assess operability reviewed 
51% of cases during screening; local decisions 
(by a collaborating experienced surgeon, as de-
fined in the study protocol) were permitted in 
the remaining 49% of cases. We completely 
agree that the availability of a new specific 
medication for patients with inoperable chronic 
thromboembolic pulmonary hypertension should 
not exclude any patient from this potentially cu-
rative surgical therapy.
In response to Egom: direct soluble guanylate 
cyclase stimulation by riociguat leads to dose-
dependent production of cGMP and vasodilatory 
effects that cannot be further maximized by co-
administration of a phosphodiesterase-5 inhibi-
tor.1 This is the rationale for individual dose 
adjustment of riociguat (according to a strict pro-
tocol) that is limited by the predefined boundar-
ies of systemic systolic blood pressure. Although 
concomitant administration of a phosphodiester-
ase-5 inhibitor could in theory result in increased 
efficacy, this would most likely occur only in pa-
tients receiving an insufficient dose of riociguat, 
which in clinical practice should not happen. 
Furthermore, PATENT PLUS (Evaluation of the 
Pharmacodynamic Effect of the Combination of 
Sildenafil and Riociguat on Blood Pressure and 
Other Safety Parameters) showed no evidence of 
a positive risk–benefit assessment when riociguat 
was combined with a standard dose of sildenafil, 
predominantly because of the number of discon-
tinuations,2 and this combination is contraindi-
cated in the prescribing information for riociguat 
in the United States and Canada.
Oh et al. note that lifelong anticoagulation is 
mandatory in patients with chronic thromboem-
bolic pulmonary hypertension. All patients re-
ceived effective oral anticoagulation for 3 months 
or more before enrollment and throughout 
CHEST-1, as stipulated in the study protocol.
Finally, the concerns raised by Post were seri-
ously considered when the study was designed in 
2006 and 2007. All local ethics committees ap-
proved the study, and all patients were informed 
about the potential risks and benefits of participat-
ing. Given the relatively short duration of the study, 
the fact that predefined criteria for discontinuation 
were implemented to allow patients to switch to 
commercially available therapy for pulmonary 
arterial hypertension if needed, and that medica-
tions specifically for pulmonary arterial hyperten-
sion are not available in all countries, it was con-
sidered justifiable to conduct the study in this way.
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Randomized Clinical Trials — Removing Obstacles
To the Editor: Reith et al. (Sept. 12  issue)1 sug-
gest that clinical trials comparing widely accept-
ed therapies should not be held to the “exces-
sively detailed informed consent” standards of 
trials involving new therapies. Their justification 
appears to be as follows: for treatment purposes, 
patients already accept the risks of well-under-
stood therapies for which evaluative data are 
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